Literature DB >> 10897019

Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study.

S A Hundahl1, B Cady, M P Cunningham, E Mazzaferri, R F McKee, J Rosai, J P Shah, A M Fremgen, A K Stewart, S Hölzer.   

Abstract

BACKGROUND: The American College of Surgeons Commission on Cancer (CoC) has conducted national Patient Care Evaluation (PCE) studies since 1976.
METHODS: Over 1500 hospitals with CoC-approved cancer programs were invited to participate in this prospective cohort study of U.S. thyroid carcinoma cases treated in 1996. Follow-up will be conducted through the National Cancer Data Base.
RESULTS: Of the 5584 cases of thyroid carcinoma, 81% were papillary, 10% follicular, 3.6% Hürthle cell, 0.5% familial medullary, 2.7% sporadic medullary, and 1.7% undifferentiated/anaplastic. Demographics and suspected risk factors were analyzed. Fine-needle aspiration of the thyroid gland (53%) or a neck lymph node (7%), thyroid nuclear scan (39%), and ultrasound (38%) constituted the most frequently utilized diagnostic modalities. The vast majority of patients with differentiated thyroid carcinoma presented with American Joint Committee on Cancer Stage I and II disease and relatively small tumors. For all histologies, near-total or total thyroidectomy constituted the dominant surgical treatment. No lymph nodes were examined in a substantial proportion of cases. Residual tumor after the surgical event could be documented in 11% of cases, hypocalcemia in 10% of cases, and recurrent laryngeal nerve injury in 1.3% of cases. Complications were most frequently associated with total thyroidectomy combined with lymph node dissection. Thirty-day mortality was 0.3%; when undifferentiated/anaplastic cancer cases were eliminated, it decreased to 0.2%. Adjuvant treatment, probably underreported in this study, consisted of hormonal suppression (50% overall) and radioiodine (50% overall).
CONCLUSIONS: In addition to offering information concerning risk factors and symptoms, the current PCE study compliments the survival information from previous NCDB reports and offers a surveillance snapshot of current management of thyroid carcinoma in the U.S. Identified opportunities for improvement of care include 1) more frequent use of fine-needle aspiration cytology in making a diagnosis; 2) more frequent use of laryngoscopy in evaluating patients preoperatively, especially those with voice change; and 3) improved lymph node resection and analysis to improve staging and, in some situations, outcomes. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 10897019     DOI: 10.1002/1097-0142(20000701)89:1<202::aid-cncr27>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  110 in total

1.  Extent of surgical intervention in case of N0 neck in head and neck cancer patients.

Authors:  Jatin P Shah
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-01-09       Impact factor: 2.503

Review 2.  Well differentiated thyroid carcinoma: current treatment.

Authors:  J Kenneth Byrd; Robert J Yawn; Christina S T Wilhoit; Nicoleta D Sora; Linda Meyers; Jyotika Fernandes; Terry Day
Journal:  Curr Treat Options Oncol       Date:  2012-03

3.  A comparative study of the surgical outcomes of robotic and conventional open modified radical neck dissection for papillary thyroid carcinoma with lateral neck node metastasis.

Authors:  Sang-Wook Kang; So Hee Lee; Jae Hyun Park; Jun Soo Jeong; Seulkee Park; Cho Rok Lee; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung; Cheong Soo Park
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

4.  Adjuvant external beam radiation for medullary thyroid carcinoma.

Authors:  Steve R Martinez; Shannon H Beal; Allen Chen; Steven L Chen; Philip D Schneider
Journal:  J Surg Oncol       Date:  2010-08-01       Impact factor: 3.454

5.  Decreased expression of p27 is associated with malignant transformation and extrathyroidal extension in papillary thyroid carcinoma.

Authors:  Sung-Im Do; Dong Hyun Kim; Jung-Ho Yang; Jung-Soo Pyo; Kyungeun Kim; Hyunjoo Lee; In-Gu Do; Dong-Hoon Kim; Seoung Wan Chae; Jin Hee Sohn
Journal:  Tumour Biol       Date:  2015-10-07

6.  Surgical decision making in the management of well-differentiated thyroid cancer.

Authors:  Natalya Chernichenko; Ashok R Shaha
Journal:  Indian J Surg Oncol       Date:  2012-05-01

7.  Aberrant expression pattern and location of cullin 1 are associated with the development of papillary carcinoma in thyroid and cyclin D1 expression.

Authors:  Sung-Im Do; Kyungeun Kim; Hyunjoo Lee; Hyun-Soo Kim; Tae Gu Do; Jisup Yun; Dong-Hoon Kim; Seoung Wan Chae; Yong Lai Park; Chan Heun Park; Jin Hee Sohn; Kyueng-Whan Min; Jung-Soo Pyo
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

8.  Single versus sequential fine-needle aspiration biopsy in the management of thyroid nodular disease.

Authors:  Julio C Furlan; Yvan C Bedard; Irving B Rosen
Journal:  Can J Surg       Date:  2005-02       Impact factor: 2.089

Review 9.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

10.  Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment.

Authors:  F Y Miasaki; A Vivaldi; R Ciampi; L Agate; P Collecchi; A Capodanno; A Pinchera; R Elisei
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.